<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32806">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679573</url>
  </required_header>
  <id_info>
    <org_study_id>ML-3341-306</org_study_id>
    <secondary_id>2015-003026-14</secondary_id>
    <nct_id>NCT02679573</nct_id>
  </id_info>
  <brief_title>Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melinta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Melinta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of delafloxacin compared to
      moxifloxacin in the treatment of adult patients with community-acquired pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine if delafloxacin, an investigational drug, is safe
      and effective in the treatment of community-acquired pneumonia compared with moxifloxacin,
      or linezolid in the case of confirmed MRSA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Assessment of Early Clinical Response</measure>
    <time_frame>96 hours after the first dose of study drug</time_frame>
    <description>Investigator assessment of clinical signs and symptoms of pneumonia with early clinical response defined as improvement in at least 2 of the following symptoms: chest pain, cough, productive sputum, and difficulty breathing and no worsening of any of the other symptoms in the ITT population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early Clinical Response with the addition of improvement in vital signs and no worsening of the 4 symptoms</measure>
    <time_frame>96 hours after the first dose of study drug</time_frame>
    <description>Investigator assessment of early clinical response with the addition of improvement in vital signs and no worsening of the following 4 symptoms: chest pain, cough, productive sputum, and difficulty breathing, required as Response in the ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome at Test of Cure</measure>
    <time_frame>5 to 10 days after the last dose of study drug</time_frame>
    <description>Clinical outcome based on the investigator's assessment of the patient's signs and symptoms of infection in the clinically evaluable and ITT populations.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">860</enrollment>
  <condition>Community Acquired Bacterial Pneumonia</condition>
  <arm_group>
    <arm_group_label>Delafloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV delafloxacin with potential to switch to oral delafloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin /linezolid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV moxifloxacin with potential to switch to oral moxifloxacin and potential to switch moxifloxacin to linezolid for confirmed MRSA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delafloxacin</intervention_name>
    <description>Antibacterial agent</description>
    <arm_group_label>Delafloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Antibacterial Agent</description>
    <arm_group_label>Moxifloxacin /linezolid</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>Antibacterial Agent</description>
    <arm_group_label>Moxifloxacin /linezolid</arm_group_label>
    <other_name>Zyvox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female 18 years of age or older

          2. Evidence of acute onset of CABP with 2 or more of the following symptoms (new or
             worsening)

               -  Cough

               -  Production of purulent sputum consistent with bacterial infection

               -  Difficulty breathing

               -  Chest pain due to pneumonia

             AND have at least 2 of the following findings:

               -  Fever (oral temperature &gt;38.0°C)

               -  Hypothermia (oral temperature &lt;35.0°C)

               -  Tachycardia (heart rate &gt;100 beats/min)

               -  Tachypnea (respiratory rate &gt;18 breaths/min)

             AND have at least 1 of the following findings:

               -  Hypoxemia (oxygen saturation &lt; 90% or PaO2 &lt; 60 mmHg) on room air or with
                  subject's baseline [pre-CABP under study] supplemental oxygen

               -  Clinical evidence of pulmonary consolidation and/or presence of pulmonary rales

               -  An elevated white blood cell count (WBC) &gt; 10,000/mm3 or 15% immature
                  neutrophils (bands), regardless of total peripheral WBC count or leukopenia with
                  WBC &lt; 4500/mm3

          3. Presence of lobar, multilobar, or patchy parenchymal infiltrate(s) consistent with
             acute bacterial pneumonia on a pulmonary imaging study within 48 hours before the
             first dose of study drug

          4. PORT risk class of II to V

          5. Must be a suitable candidate for possible IV to oral switch antibiotic therapy and
             must also be able to swallow large tablets/capsules intact without crushing

        Exclusion Criteria:

          1. A medical history of significant hypersensitivity or allergic reaction to antibiotics
             of the quinolone or oxazolidinone class or study drug excipients according to the
             investigator

          2. Any infection expected to require other systemic antibiotics in addition to study
             drug

          3. Receipt of systemic antibiotic therapy in the 7 days before enrollment

               -  one dose of a single, potentially effective, short-acting antibacterial drug or
                  drug regimen for CABP within 24 hours before enrollment is allowed - limited to
                  25% of enrolled patients

               -  At least 48 hours of antibiotic therapy for CABP and the clinic notes document
                  treatment failure (i.e., not by patient history or pulmonary imaging alone) with
                  new or worsening symptoms while on pre-study therapy is also allowed

          4. Respiratory infection confirmed or suspected to be secondary to hospital-acquired or
             ventilator-associated pneumonia or requires treatment in an intensive care setting,
             or mechanical ventilation

          5. Current or suspected diagnosis of viral, fungal, or aspiration pneumonia,
             noninfectious causes of pulmonary infiltrates, lung cancer, cystic fibrosis,
             tuberculosis, empyema (not including sterile parapneumonic effusions)

          6. Known anatomical or pathological obstruction or history of bronchiectasis or GOLD
             Stage 4 COPD or history of post obstructive pneumonia

          7. Severely compromised immune system

          8. Other exclusions include those described in the safety label for drugs in the
             quinolone and /or oxazolidinone classes such as QT prolongation, proarrhythmic
             conditions, concomitant use of drugs known to cause QT prolongation, peripheral
             neuropathy, tendon disorders, history of myasthenia gravis, liver disease, severe
             renal disease, seizures and concomitant use of MAO A or B inhibitor agents and
             adrenergic serotonergic agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sue Cammarata, MD</last_name>
    <role>Study Director</role>
    <affiliation>Melinta Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Megan Quintas</last_name>
    <phone>312-724-9400</phone>
    <email>clinicaltrials@melinta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Debary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Liepaja</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Chrzanow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Vsevolozhsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Sremska Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Golnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta 306 Study Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>January 27, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
